Pharmaceutical and biotechnology major Wockhardt Ltd. said it had launched on April 23 an authorized generic version of four strengths - 50mg, 75mg, 125mg and 200mg - of the triple-drug combination product containing Levodopa, Carbidopa and Entacapone, which are used in treatment of Parkinson's disease.
The Levodopa plus Carbidopa plus Entacapone tablet is the generic name for the brand Stalevo owned by Orion Corporation and marketed in the US by Novartis.
The company said the product was entitled to 180-days of exclusivity.
Incidence of Parkinson's disease is increasing worldwide. As per IMS Health data, the total market for this product in the US is around $55 million for the above four strengths and even after the 180 days exclusivity the number of competitors to enter the market is expected to be very limited.
Chairman Habil Khorakiwala said, "Wockhardt was the first-to-file with paragraph-IV certification on four out of six strengths of this product. Pursuant to a settlement of the litigation between Wockhardt and Orion Corporation, Finland, the holder of the NDA, Wockhardt came to an arrangement to launch an authorized generic version with 180-days of exclusivity. The product involved development of a complex API as well as a triple-drug combination formulation."
At the BSE, Wockhardt shares are currently trading at Rs.692.35 down 0.16 percent from the previous close.
For comments and feedback: editorial@rttnews.com